Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembro-FLASH
2022-501458-13-01Phase 2Authorised
- Sponsor
- University of Cologne
- Start
- Sep 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and brentuximab vedotin in classical Hodgkin lymphoma (cHL), sponsored by University of Cologne. Primary endpoint: 1-year progression-free survival estimate. Planned start Sep 2025; status: authorised.
02
Drugs
pembrolizumabbrentuximab vedotin
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2022-501458-13-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501458-13-01.